ipragliflozin: Clinical Trials

55 trials of ipragliflozin, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

52 completed, 2 terminated, 1 recruiting. 22 Phase 1, 19 Phase 3, 5 Phase 2, 5 Phase 4.

By phase and status

Phase	Trials	Status
Phase 1	22	Completed 22
Phase 3	19	Completed 18, Terminated 1
Phase 2	5	Completed 5
Phase 4	5	Completed 4, Terminated 1

Follow ipragliflozin: new trials by email Literature Review of ipragliflozin trials Research Report on ipragliflozin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study SGLT2 inhibitor - Myocardial Infarction, Diabetes Mellitus, Type 2		Recruiting	Kiyuk Chang	1000	2020-08-01	2025-01-03
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus	Phase 3	Completed	Seoul National University Bundang Hospital	170	2017-04-25	2022-10-04
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria metformin, ipragliflozin, glimepiride - Type 2 Diabetes Mellitus	Phase 4	Terminated	Astellas Pharma Korea, Inc.	33	2017-04-25	2024-11-08
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus ipragliflozin, Placebo, Insulin Therapy - Type 1 Diabetes Mellitus	Phase 3	Completed	Astellas Pharma Inc	175	2016-08-29	2024-11-12
Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy Ipragliflozin, Insulin - Type 2 Diabetes Mellitus	Phase 4	Completed	Astellas Pharma Inc	103	2016-07-29	2024-11-12
A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Ipragliflozin L-proline, Metformin, Placebo - Type 2 Diabetes Mellitus	Phase 3	Completed	Astellas Pharma Europe B.V.	268	2016-05-11	2024-11-12
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Ipragliflozin, metformin with pioglitazone - Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)	Phase 4	Completed	Yonsei University	44	2016-04-26	2017-06-23
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843) Ipragliflozin, Placebo, Sitagliptin - Type 2 Diabetes Mellitus	Phase 3	Completed	Merck Sharp & Dohme LLC	143	2015-11-09	2018-09-04
Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842) Sitagliptin, Placebo, Ipragliflozin - Type 2 Diabetes Mellitus	Phase 3	Completed	Merck Sharp & Dohme LLC	141	2015-11-05	2018-08-31
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849) Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus	Phase 3	Completed	Merck Sharp & Dohme LLC	77	2015-10-26	2018-09-04
Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus Placebo, ASP1941 - Type 1 Diabetes Mellitus	Phase 2	Completed	Astellas Pharma Inc	43	2015-09-01	2024-11-12
A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin ASP1941, Placebo - Type 2 Diabetes Mellitus	Phase 3	Completed	Astellas Pharma Korea, Inc.	143	2015-06-22	2024-11-12
Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes Ipragliflozin (SGLT2 inhibitor) - Diabetes Mellitus, Type 2		Completed	Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan	231	2014-11-01	2018-04-17
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM) Ipragliflozin - Type 2 Diabetes Mellitus	Phase 4	Completed	Astellas Pharma Inc	100	2014-10-08	2024-11-08
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients ipragliflozin - Type 2 Diabetes		Completed	Astellas Pharma Inc	11412	2014-07-17	2024-10-22
The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients Suglat® - Type 2 Diabetes		Completed	Astellas Pharma Inc	8687	2014-04-01	2015-10-15
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus ipragliflozin, placebo - Type 2 Diabetes Mellitus	Phase 4	Completed	Astellas Pharma Inc	262	2014-03-31	2024-11-08
A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets ASP1941 - Healthy, Plasma Concentration of ASP1941	Phase 1	Completed	Astellas Pharma Inc	32	2013-09-01	2014-02-07
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients ipragliflozin - Type 2 Diabetes Mellitus	Phase 3	Completed	Astellas Pharma Inc	174	2012-05-25	2024-11-08
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus ASP1941, acarbose, Placebo - Type II Diabetes Mellitus	Phase 3	Terminated	Astellas Pharma Inc	46	2012-04-23	2024-11-12

ipragliflozin: Clinical Trials

55 trials of ipragliflozin, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

By phase and status

Trials newest first · largest first

Conditions studied

Sponsors

Countries

Top investigators

Results publications

NIH funding